Novel role of HDAC inhibitors in AML1/ETO AML cells: Activation of apoptosis and phagocytosis through induction of annexin A1

Cell Death and Differentiation

Volumn 14, Issue 8, 2007, Pages 1443-1456

  Tabe, Y ^a,b   Jin, L ^b   Contractor, R ^a   Gold, D ^a   Ruvolo, P ^c   Radke, S ^d   Xu, Y ^b   Tsutusmi Ishii, Y ^b   Miyake, K ^b   Miyake, N ^b   Kondo, S ^b   Ohsaka, A ^b   Nagaoka, I ^b   Andreeff, M ^a   Konopleva, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FR 901228; HISTONE DEACETYLASE INHIBITOR; LIPOCORTIN 1; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX1; VORINOSTAT;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL MEMBRANE; CHROMOSOME 21; CHROMOSOME 8; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CONTROLLED STUDY; DNA MICROARRAY; DNA TRANSFECTION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MACROPHAGE; NUCLEOTIDE SEQUENCE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; UNINDEXED SEQUENCE; UPREGULATION;

ACETYLATION; ANNEXIN A1; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DEPSIPEPTIDES; DNA, COMPLEMENTARY; ENZYME INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MACROPHAGES; ONCOGENE PROTEINS, FUSION; PHAGOCYTOSIS; UP-REGULATION;

EID: 34447646156     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402139     Document Type: Article

References (40)

1. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoRmSin3HDAC1 complex. Proc Natl Acad Sci USA 1998; 95: 10860-10865.
2. Strahl B, Alis CD. The language of covalent histone modifications. Nature 2000; 403: 41-45.
3. Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 2001; 11: 162-166.
4. Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia: New therapeutic paradigms. Blood 1999; 94: 417-428.
5. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005; 23: 3971-3993.
6. Kosugi H, Ito M, Yamamoto Y, Towatari M, Ito M, Ueda R et al. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-acid/acid mice. Jpn J Cancer Res 2001; 92: 529-536.
7. Nebbloso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11: 77-84.
8. Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: Impact of depsipeptite on molecular markers, therapeutic targets, and mechanism of resistance. Blood 2004; 103: 4636-4643.
9. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2005; 24: 166-173.
10. Garcia Pedrero JM, Fernandez MP, Morgan RO, Herrero Zapatero A, Gonzalez MV, Suarez Nieto C et al. Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am J Pathol 2004; 164: 73-79.
11. Debret R, El Btaouri H, Duca L, Rahman I, Radke S, Heye B et al. Annexin A1 processing is associated with caspase-dependent apoptosis in BZR cells. FEBS Lett 2003; 546: 195-202.
12. Solito E, de Coupade C, Canaider S, Goulding NJ, Perretti M. Transfection of annexin 1 in monocytic cells produces a high degree of spontaneous and stimulated apoptosis associated with caspase-3 activation. Br J Pharmacol 2001; 133: 217-228.
13. Raynal P, Pollard HB. Annexins: The problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta 1994; 1197 63-93.
14. Solito E, Kamal A, Russo-Marie F, Buckingham JC, Marullo S, Perretti M. A novel calcium-dependent proapoptolic effect of annexin 1 on human neutrophils. FASEB J 2003; 17: 1544-1546.
15. Borisenko GG, Matsura T, Liu SX, Tyurin VA, Jianfei J, Serinkan FB et al. Macrophage recognition of externalized phosphatidylserine and phagocytosis of apoptotic Jurkat cells - existence of a threshold. Arch Biochem Biophys 2003; 413: 41-52.
16. Sutheesophon K, Nishimura N, Kobayashi Y, Furukawa Y, Kawano M, Itoh K et al. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). J Cell Physiol 2005; 203: 387-397.
17. 2 and PAF. J Clin Invest 1998; 101: 890-898.
18. Lutterbach B, Westendorf JJ, Lingo B, Patten A, Moniwa M, Davie JR et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-Cor and mSin3 corepressors. Mol Cell Biol 1998; 18: 7176-7184.
19. Westendorf JJ, Yamamoto CM, Lenny N, Downing JR, Selsted ME, Hiebert SW. The t(8;21) fusion product, AML1-ETO, associates with C/EBPα, inhibits C/EBPa-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol 1998; 18: 322-333.
20. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G et al. AML1-ETO downregulates the granulocytic differentiation factor C/ EBPalpha in t(8;21) myeloid leukemia. Nat Med 2001; 7: 444-451.
21. Arur S, Uche UE, Razaul K, Fong M, Scranton V, Cowan AE et al. Annexin I is an endogenous ligand that mediates apoptotic cell engulfment. Dev Cell 2003; 4: 587-598.
22. Perretti M, Solito E. Annexin 1 and neutrophil apoptosis. Biochem Soc Trans 2004; 32: 507-510.
23. Gelmett V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998; 18: 7185-7191.
24. Shimada H, Ichikawa H, Nakamura S, Katsu R, Iwasa M, Kitabayashi I et al. Analysis of genes under the downstream control of the t(8;21) fusion protein AML1-MTG8: Overexpression of the TIS11b (ERF-1, cMG1) gene induces myeloid cell proliferation in response to G-CSF. Blood 2000; 96: 655-663.
25. Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004; 24: 2890-2904.
26. Linggi B, Muller-Tidow C, van de Locht L, Hu M, Nip J, Serve H et al. The t(8;21) fusion protein, AMLI ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 2002: 8: 743-750.
27. Yang G, Khalaf W, van de Locht L, Jansen JH, Gao M, Thompson MA et al. Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein. Mol Cell Biol 2005; 25: 5869-5879.
28. Uchida H, Zhang J, Nimer SD. AML1A and AML1B can transactivate the human IL-3 promoter. J Immunol 1997; 158: 2251-2258.
29. Yang G, Thompson MA, Brandt SJ, Hiebert SW. Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Oncogene 2007; 26: 91-101.
30. Furumal R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62 4916-4921.
31. Alvarez-Martinez MT, Porte F, Liautard JP, Sri Widada J. Effects of profilin-annexin I association on some properties of both profilin and annexin I: Modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes. Biochim Biophys Acta 1997; 1339: 331-340.
32. Canaider S, Solito E, DeCoupade C, Flower RJ, Russo-Marie F, Gouldrig NJ et al. Increased apoptosis in U937 cells over-expressing lipocortin 1 (annexin I). Life Sci 2000; 66: L265-L270.
33. Kwon SH, Ahn SH, Kim YK, Bae G-U, Yoon JW, Hong S et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 2002; 277: 2073-2080.
34. Reville K, Crean JK, Vivers S, Dransfield I, Godson C. Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: Implications for phagocytosis of apoptotic leukocytes. J Immunol 2006; 176: 1878-1888.
35. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959-967.
36. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991; 77: 2031-2036.
37. Matozaki S, Nakagawa T, Kawaguchi R, Aozaki R, Tsutsumi M, Murayama T et al. Establishment of a myeloid leukaemic cell line (SKNO-1) from a patient with t(8;21) who acquired monosomy 17 during disease progression. Br J Haematol 1995; 89: 805-811.
38. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77 1080-1086.
39. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection, Proc Natl Acad Sci USA 2001; 98: 31-36.
40. Baguet A, Sun X, Arroll T, Krumm A, Bix M. Intergenic transcription is not required in Th2 cells to maintain histone acetylation and transcriptional permissiveness at the II4-II13 locus. J Immunol 2005; 175: 8146-8153.